1690-P: Clinical Outcomes among Nondiabetic Obese Population with Concomitant Metabolic Dysfunction–Associated Steatotic Liver Disease-A Nationwide Study

Obesity, a disease increasing cardiometabolic risks and mortality, often accompanies metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is characterized by fat accumulation in the liver without other secondary causes. This study explores clinical outcomes in obese patients without DM co-diagnosed with MASLD. Conducted as an observational study, it utilized data from the National Inpatient Sample from 2017 to 2020 focusing on obese adults over 18 years, with a BMI >30 kg/m^2, and MASLD diagnosis, excluding those under 18 or with DM. Multivariable logistic and Poisson regression analyses determined the clinical outcomes, considering a p-value